LIVE TV
ZEE Business
ZEE BUSINESS
हिंदी में पढ़ें  हिंदी में पढ़ें
Live TV
Live TV
  • Home
  • Budget 2021
  • Personal Finance
    • PPF
    • Mutual Funds
    • Income tax
    • EPFO
    • Income Tax Calculator
    • Personal Loan Calculator
    • Car Loan Calculator
    • Home Loan Calculator
    • SIP calculator
    • SWP Calculator
    • MF Returns Calculator
    • Lumpsum Calculator
  • India
    • Companies
    • Property
    • Startups
    • Uidai
  • Economy
    • Aviation
  • Tech
    • Mobiles
    • Apps
  • Auto
    • Cars
    • Bikes
  • Markets
    • Commodities
    • Currency
  • Jobs
  • Indian Railways
  • World
    • Economy
    • Politics
    • Markets
  • videos
  • photos
  • Authors
  • More ...
    • VIDEOS
    • PHOTOS
Read in App
Business News » Companies News

Lupin’s JV YL Biologics announces successful clinical trial of rheumatoid arthritis drug

The study of YLB113 was a multinational  randomised  double-blind controlled trial of 52 weeks duratio

  • Twitter
  • Facebook
  • Linkedin
  • whatapp
  • View in App
Lupin’s JV YL Biologics announces successful clinical trial of rheumatoid arthritis drug
The study was conducted at 110 rheumatology clinics across Japan, Europe and India. Image source: Reuters
Written By: ZeeBiz WebTeam
Updated: Wed, Feb 07, 2018
01:53 pm
ZeeBiz WebDesk

YL Biologics,  a joint venture between Lupin and Yoshindo, announced today said that its phase-III clinical studies on a biosimilar version of Etanercept (YLB113) has met with a successful outcome.
 
The study of YLB113 was a multinational randomised double-blind controlled trial of 52 weeks duration which included more than 500 patients with rheumatoid arthritis (RA) in 11 countries,  Lupin said in a statement.
 
"It compared YLB113’s efficacy and safety directly against Enbrel® (of Amgen/Pfizer) which has a global market of $11 billion, and is a widely successful biologic agent globally used for the treatment of multiple autoimmune disorders including RA." 
 
The study was conducted at 110 rheumatology clinics across Japan, Europe and India which included over 260 Japanese patients from 62 rheumatology clinics, a scale that is distinct for a global RA trial in Japan.
 
The primary endpoint was an equivalent improvement in rheumatoid arthritis, as measured by American College of Rheumatology 20 (ACR20) response rate. 
 
The ACR20 response rate of YLB113 has been found to be within a pre-defined equivalence margin that is expected by most advanced regulatory agencies for marketing authorisation. In addition, safety and immunogenicity (antibody formation) of YLB113 was also found to be similar to Enbrel® indicating therapeutic equivalence, the statement said.
 
“We are excited by the positive results from the Phase III trial. This helps us put together a robust regulatory dossier intended for global regulatory filings for YLB113.  We currently have multiple high value biosimilar candidates in our late-stage global development pipeline” said Nilesh Gupta, MD of Lupin Limited.
 
Lupin is a significant player in the cardiovascular, diabetology, asthma, paediatric, CNS, GI, anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.
 
For the financial year ended March 31, 2017, Lupin’s consolidated sales and net profit stood at Rs 171,198 million ($2.55 billion) and Rs 25,575 million ($381 million), respectively. 
 

Get Latest Business News, Stock Market Updates and Videos; Check your tax outgo through Income Tax Calculator and save money through our Personal Finance coverage. Check Business Breaking News Live on Zee Business Twitter and Facebook. Subscribe on YouTube.

TAGS:
YL BiologicsLupin and YoshindoEtanercept (YLB113)rheumatoid arthritisclinical trialbiologicbiosimilar
RELATED NEWS

LATEST NEWS

Super hi-tech driverless pod taxis for Noida Aiport! Check Yogi Adityanath government's big plans for Jewar

Listing facilitation! Ahead of LIC IPO, authorised capital boost of Rs 25,000 crores - All you need to know

Rakesh Jhunjhunwala stocks: This Big Bull-owned MULTIBAGGER has delivered more than 42 pct in less than two month

Stock Market Outlook: Focus will be on these - Check what share bazaar experts, analysts opined

Andhra Pradesh trade body to promote IP rights, registration for MSMEs

Announcement LIVE: IIT JEE Main 2021 Result February - Date, time, declaration on NTA website direct link jeemain.nta.nic.in, download answer key, score checking and more

Life Insurance Coverage Calculator: Simple cover calculation in just 3 steps - EXPLAINED

West Bengal Elections: PM Narendra Modi launches blistering attack on Mamata Banerjee - Top quotes

Mumbai-Ahmedabad Bullet Train: Tech bids open for bridge project - Check latest news development

REVEALED! What gave a massive 400% jump to FDI in computer software, hardware during Apr-Dec 2020

  • India News
  • World News
  • Companies News
  • Market News
  • Personal Finance News
  • Technology News
  • Automobile News
  • Small Business News
  • Income Tax Calculator
  • Live TV
  • Videos
  • Photos
  • Author
  • Rss Feed
  • Advertise with us
  • Privacy Policy
  • Legal Disclaimer

Latest Trending Updates

  • EPFO
  • Budget 2020
  • Income Tax Return
  • Auto Expo 2020
  • Home Loan
  • Business News

Trending Topics

  • Income Tax
  • income Tax Calculator
  • 7th Pay Commission
  • Reserve Bank of India
  • GST
  • Latest Business News

Follow us on

zeebiz
zeebiz

Partner Sites

  • Zee News
  • Hindi News
  • Marathi News
  • Bengali News
  • Tamil News
  • Malayalam News
  • Gujarati News
  • Telugu News
  • Kannada News
  • DNA
  • WION
Copyright © Zee Media Corporation Ltd. All rights reserved